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Young age can be an independent prognostic factor for adverse
prognosis in women with breast carcinoma (BC). In younger women,
BC exhibited more aggressive pathological features than older
women, indicating differences in biology. Frequent alterations in
chromosomal (chr.) 3p22.3 in different malignancies indicated the
existence of multiple candidate tumor suppressor genes (TSG) in
this region, yet its association with BC remains unclear. In an effort
to understand the differences in molecular pathogenesis in two age
groups of BC, detailed analysis of alterations at chr.3p22.3 region
was carried out in 47 early onset (group-A: 40 years) and 59 late-
onset (group-A: >40 years) BC samples. Deletion mapping of the
four candidate TSG, hMLH1, APRG1, ITGA9 and RBSP3/HYA22,
located within 1 Mb of chr.3p22.3 showed high deletion in hMLH1
and RBSP3/HYA22 genes. Frequent methylation was also observed
in these genes and significantly associated with their deletion.
Quantitative messenger RNA (mRNA) expression and immuno-
histochemical analysis showed down-regulation of these genes.
Alterations (deletion/methylation) of hMLH1 were significantly
associated with RBSP3/HYA22 in group-A (P = 0.02). Significant poor
survival in group-A patients with alterations in hMLH1 and RBSP3/
HYA22 and the same in group-B patients with hMLH1 alterations
indicated their importance as prognostic markers. Differential
association of alterations of these genes with higher histological
grades, more advanced stages and positive lymph node involvement
were also seen. Thus, the present study suggests hMLH1 and
RBSP3/HYA22 to be candidate TSG associated with development of
both early and late-onset BC undergoing frequent genetic and
epigenetic alteration and having significant prognostic implications.
(Cancer Sci 2008; 99: 1984–1991)
Breast cancer (BC), is the third most prevalent malignancyand primary cause of death in women worldwide.(1) In
India, it accounts for 19% of all cancers among women, and is
the second most common cancer when both sexes are considered
together, whereas about 23% of eastern Indian women suffer
from this disease.(2,3) Considering the age at onset of tumor, BC
can be classified as early onset (group-A: ≤40 years) and late-onset
(group-B: >40 years).(4,5) However, the cut-off value for early onset
BC varies among investigators, ranging from 35–50 years.(6,7)
Despite this discrepancy, younger women with BC exhibit more
aggressive pathological features, including large tumor size of
higher grade, presence of positive lymph nodes, absence of
steroid receptors and high S-phase fraction, than older women
with BC.(6,7) Another report showed that, in an Asian population,
BC patients below 40 years have tumors with a poorer
prognostic profile. However, this did not translate into poorer
overall survival and might be attributable to more aggressive
adjuvant treatment of younger patients.(8) All these reports
suggested early onset BC to be a biologically separate disease
that independently predicts more adverse outcomes. Thus, the
molecular analysis of BC in the two age groups is essential to
ascertain the differences in pathogenesis, if any. Our previous
studies on chromosomes (chrs.) 1p/q, 9p/q, 11p/q, 13q and 17p/
q have shown differences in pattern of molecular alterations in
the two age groups.(6,7,9,10) So, to find out the differences in
pathogenesis in early and late-onset BC, detailed molecular
analysis is pertinent.
Cytogenetic analyses detected frequent loss of chromosome
3p (chr.3p) in a variety of malignancies.(11–16) Loss of heterozy-
gosity (LOH) at chrs.3p25, 3p22–24, 3p21.3, 3p21.2–21.3, 3p14.2,
3p14.3 and 3p12 reported in breast cancers suggest the presence
of tumor suppressor genes (TSG) within these deleted regions.(17,18)
Among these deleted regions, chr.3p22.3 harbors multiple
candidate TSG viz. hMLH1, APRG1, ITGA9 and RBSP3/HYA22
within a 1-megabase (Mb) region.
The DNA mismatch repair gene (MMR) hMLH1, located
37 Mb from chr.3p-ter, was reported to be altered in a variety of
malignancies including BC. Varying frequency of mutations
(10–47%) and methylation (32–44%) of hMLH1 have been
reported in both breast cancer cell lines and primary BC.(18–23)
Association between mutation and methylation was seen in
sporadic BC resulting in microsatellite instability (MSI).(19)
Moreover, loss in expression of hMLH1 in BC with no apparent
methylation point towards other alternative mechanisms contrib-
uting to loss of function.(24) The APRG1 gene located 0.4 Mb
centromeric to hMHL1 has been implicated in cell membrane
interactions and reported to be a candidate TSG associated with
BC.(25) Another candidate TSG, ITGA9 (integrin α9 subunit)
gene located 0.4 Mb further down-stream of APRG1, is a member
of the β1 integrin family expressed by stratified squamous
epithelium and associated with cell differentiation and growth.(26)
The RBSP3/HYA22 (CTDSPL) gene located 190 kilobase (Kb)
downstream of ITGA9 was reported to undergo frequent
homozygous (HD) and hemizygous deletion (HED) in various
malignancies including BC.(26,27) RBSP3/HYA22 is suggested to
be a member of a previously uncharacterized family of small
C-terminal domain (CTD) phosphatases that catalyzes the
dephosphorylation of Ser 5 within the consensus repeat of the
largest RNA polymerase II subunit, thus affecting gene tran-
scription.(29) Missense and nonsense mutations of RBSP3/HYA22
in different tumors have been reported. RBSP3/HYA22 plays a
direct role in dephosphorylation of ppRB, presumably leading to
blocks in the cell cycle at the G1–S boundary.(27) It is also
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reported to have tumor suppressive role in both in vitro and
in vivo systems.(27)
Hence, it is evident that cumulative increase in genetic insta-
bility and cellular proliferation could be a consequence of
genetic and epigenetic alterations of these genes. Study of
coalterations of these genes could be useful in devising a diag-
nostic and prognostic marker. So, to delineate the molecular
pathogenesis of early and late-onset BC, attempts were made in
the present study to analyze the alterations (deletion, methylation
and expression) in these genes and correlate them with different
clinico-pathological parameters.
Materials and Methods
Patients, tumor tissues and cell lines. Forty-seven early-onset
(group-A) and fifty-nine late-onset (group-B) sporadic BC
samples and their corresponding normal tissues or peripheral
blood leukocytes (PBL) were randomly collected over a period
of 9 years (1999–2007) from 104 unrelated patients undergoing
surgery at the hospital of Chittaranjan National Cancer Institute,
Kolkata, India and stored at –80°C. Informed consent from
patients and Research Ethics Committee of the institute were
obtained. All tumors were graded and staged according to
International Union Against Cancer (UICC) tumor size,
lymph node, metastasis (TNM) classification.(30) Detailed
clinico-pathological histories of the patients are presented in
Table 1. Part of the freshly operated tissues was directly
collected in TRIzol reagent (Invitrogen, USA) for RNA isolation
and the rest for DNA extraction. The BC cell line MCF-7 was
obtained from American Type Culture Collection (ATCC) and
grown according to ATCC instructions.
Microdissection and DNA extraction. Cryosections (5 μm) were
microdissected under a dissecting microscope (Leica MZ 16)
using surgical blades to remove contaminant normal cells. Samples
containing at least 70–80% tumor cells were taken for DNA
isolation via proteinase-K digestion, followed by phenol/
chloroform extraction procedure.(31)
Deletion analysis of the chr.3p22.3 region. Standard polymerase
chain reaction (PCR) analysis with (γ-p32) adenosine triphosphate
(ATP) end-labeled forward primer was done using micr-
osatellite markers at chr.3p22.3 intragenic to different candidate
genes.(31,32) The markers D3S1611 and D3S1007 located intragenic
to hMLH1, D3S3623 at APRG1 intron 1–2, D3S3880 at ITGA9
3′untranslated region (UTR) region and D3S4237 at RBSP3/
HYA22 3′UTR region (telomeric to centromeric) were taken for
analysis. Primers are listed in Supplement Table 1. All markers
were selected on the basis of their map positions and
heterozygosity (Ensembl release 44; Genome Database). PCR
conditions include a 30 s denaturing step at 95°C, 30 s at
appropriate annealing temperature (55–60°C) and 1 min at
72°C followed by final extension at 72°C for 7 min. PCR
products were electrophoresed in 8 M urea containing 7%
denaturing polyacrylamide sequencing gel and autoradiographed.
Multiplex PCR was done to see homozygous/hemizygous
(HD/HED) deletion in the non-informative markers (D3S3880,
D3S4237).(31,32) The SST (Somatostatin precursor; UniSTS_NUM
49790) microsatellite marker at chr.3q27.3 was used as control
(CL) owing to low frequency of alterations seen in BC (data not
shown). Primer seqeunces are in Supplement Table 1. The PCR
products were run on 2% agarose gel, stained with ethidium
bromide and visualized under UV transluminator.
Using a densitometric scanner (Bio-Rad GS-800, USA) the
number of alleles at LOI (locus of interest) was determined from
the signal intensities according to the following formula:
where T = tumor DNA, N = normal DNA, CL = control and
LOI = locus of interest.
Allelic values of ≤0.5, 0.9–1.7, ≥1.8 to <5.0 and >5.0 will be
considered as homozygous deletion (HD), hemizygous deletion
(HED), retention of both alleles (RA) and amplification of the
alleles respectively.(33)
PCR based methylation sensitive restriction analysis (MSRA). The
methylation analysis of hMLH1 and RBSP3/HYA22 gene
promoters was carried out by a methylation-sensitive restriction
analysis (MSRA).(34) Approximately, 100 ng of paired DNA samples
were individually digested overnight with a methyl-sensitive
restriction enzyme HpaII and its methylation insensitive isosch-
izomer MspI separately (Roche Diagnostics, Germany). The
same digestion mixture was used for PCR analysis of all the
genes and controls. Furthermore, mock digestion was carried
out with each sample without any restriction enzymes. Primer
sequences were: hMLH1, – 670 FP: 5′-CGCTCGTAGTATTCGTGC-
3′ to – 61 RP: 5′-ACCTCAGTGCCTCGTGCTCAC-3′; RBSP3/
HYA22, –682 FP: 5′-ACTCCTCCCCACATCTCTCA-3′ to – 490
RP: 5′-CGACACAGGGTGAGTGGAG-3′ in respect to transcription
start site. Promoter region of hMLH1 gene harbored four
CCGG-recognition sites for the above restriction enzymes,
whereas there is only one CCGG site in the RBSP3/HYA22
promoter. To avoid false positivity, MSRA was done taking two
controls: (i) 445-bp fragment of the β-3A adaptin gene (K1: has
restriction site both HpaII and MspI enzymes but is never
methylated) at chr.5q14.1 was used as digestion control; and (ii)
a 229-bp fragment of the RARβ2 exon-1 (K2) at chr.3p24.2 was
used as integrity control and contains no recognition sites for the
above enzymes.(35)
Quantitative real-time PCR (Q-PCR). The mRNA expression of
hMLH1 and RBSP3/HYA22 genes in normal breast tissue (n = 6)
and primary BC (n = 14) and one breast cancer cell line (MCF-7)
was analyzed by quantitative real-time (Q-PCR). Total RNA was
isolated from samples using TRIzol reagent according to the
manufacturer’s protocol (Ambion, USA). Complementary-DNA
(cDNA) was synthesized from 1 μg total RNA using Random
hexamer (Invitrogen, USA) and Superscript III (Invitrogen, USA)
according to manufacturer’s protocol. PCR was performed in 40
Table 1. Clinico-pathological parameters of early and late-onset breast
cancer
Clinical features
Group A Group B
Case
Average 
age (years)
Case
Average 
age (years)
Histological type
Ductal 45 34 59 53
Lobular 2 28 0 –
Clinical stage
Stage I 1 40 2 48
Stage II 7 33 21 51
Stage III 36 35 33 53
Stage IV 3 37 3 57
Sex
Male 0 – 3 52
Female 45 35 56 52
Tumor 
differentiation
Well 4 32 8 52
Moderate 32 33 39 47
Poor 11 38 12 56
Lymph node
Positive 33 35 48 52
Negative 14 31 11 51
Allele Number= 2 LOI(T)/CT(T)
LOI(N)/CL(N)×
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cycles on an ABI Prism 7500 using Power SYBR Green PCR
Master Mix (Applied Biosystems, USA) in a final volume of
15 μL. Each sample was run in triplicates and the average value
was considered for analysis. Relative quantities (ΔΔCt) were
obtained by normalization against human β2-microglobulin gene.(36)
Primers for Q-PCR were: hMLH1, F.P. 5′-ttctcaggttatcggagccagcac-3′;
R.P. 5′-cttcgtcccaattcacctcagtgg-3′ and RBSP3/HYA22, F.P.
5′-aggtgaccaaccccaagga-3′; and R.P. 5′-tcacggaagcagcagaagaa-3′.
Immunohistochemistry. Immunostaining of hMLH1 was done
in 20 primary BC samples using the avidin–biotin–peroxidase
complex (ABC) staining kit according to manufacturers protocol
(Santa Cruz Biotechnology, CA, USA). About 3–5 μm paraffin
sections were de-paraffinized, rehydrated and reacted overnight
with primary antibodies (rabbit polyclonal immunoglobulin G
[IgG] sc-581 for hMLH1; Santa Cruz, CA, USA) at a dilution of
1:100 at 4°C. Horseradish-peroxidase (HRP)-conjugated goat
antirabbit secondary antibody (sc-2004) was added at 1:500
dilutions. The slides were developed using 3–3′ diamin-
obenzidine (DAB) as the chromogen and counterstained with
hematoxylin. The staining intensity (– = negative, + = weak,
2+ = moderate and 3+ = strong) and the percentage of positive
cells (– = 0%, + = 1–24%, 2+ = 25–49% and 3+ = 50–100%)
were evaluated by two observers independently.(19)
Statistical analysis of clinical data. Fisher’s exact test was used
to determine the association between genetic profile of tumors
and different clinico-pathological features. Survival analysis was
performed according to Kaplan–Meier method. Post-operative
overall survival was measured from the date of surgery to the
date of last follow-up or death (up to 5 years). Probability value
(P-value) ≤0.05 was considered statistically significant. All
statistical analyses were performed using statistical programs
EpiInfo 6.04b and SPSS 10.0 (SPSS, Chicago, IL, USA).
Results
Deletion analysis of chr.3p22.3 region. Overall deletion noted in
the entire 1 Mb analyzed region of chr.3p22.3 was seen to be
32% (15/47) in group-A and 37% (22/59) in group-B samples.
Microsatellite analysis identified deletion in hMLH1, APRG1,
ITGA9 and RBSP3/HYA22 genes in both age groups of BC. In
group-A, hMLH1 showed highest 38% (12/32) deletion followed
by RBSP3/HYA22 (30%: 14/47), APRG1 (16%: 5/32) and ITGA9
(15%: 7/47). Likewise, in group-B, 32% (12/38) samples showed
deletion in hMLH1 followed by RBSP3/HYA22 (24%: 14/59),
ITGA9 (14%: 8/59) and APRG1 (13%: 4/32). Seven BC samples
in group-A (#2737, 983, 5901, 588, 2972 L, 3156, 3266) and six
in group-B (#2587, 148, 1186, 5213, 2766, 563) showed deletion
or non-informativeness (homozygous condition) of the entire
studied region indicating loss of the entire region. Five samples
in both groups showed homozygous deletion (HD) in RBSP3/
HYA22 (Figs 1, 2 and 3a,d). Microsatellite size alteration (MA)
was observed only in 3 out of 106 samples (#5595, 3990, 1273)
(Fig. 3b), whereas another sample (#7) showed loss in one allele
and microsatellite size alteration of the other allele (LMA)
(Fig. 3c). Higher frequency of deletion in hMLH1 and RBSP3/
HYA22 in both the age groups compared to APRG1 and ITGA9,
indicating that they were the candidate TSG associated with
pathogenesis in both age groups of BC.
In both groups, deletion in APRG1, ITGA9 and RBSP3/HYA22
showed significant association (Table 2), whereas hMLH1 dele-
tion showed significant association with other genes in group-A
and with ITGA9 in group-B.
Methylation analysis of hMLH1 and RBSP3/HYA22 gene promoters.
Methylation analysis of hMLH1 and RBSP3/HYA22 were
performed owing to their high frequency of deletion in both age
groups. Higher frequency of methylation in hMLH1 promoter
was seen in group-A (45%: 21/47) than group-B (34%: 20/59).
However, comparable frequencies of methylation in RBSP3/
HYA22 promoter was observed in both group-A (38%: 18/47)
and group-B (32%: 19/59) (Figs 1, 2 and 4a,b). Concomitant
methylation in hMLH1 and RBSP3/HYA22 promoters were seen
in 11 group-A and 7 group-B samples. However, no association was
seen between methylation of these two genes in either group.
Association between overall alterations of hMLH1 and RBSP3/
HYA22. Either deletion or methylation in any one of these genes
were seen in about 64% group-A and 61% group-B samples,
Fig. 1. Schematic representation of the pattern of alterations in chromosome 3p22.3 in Early-Onset (≤40 years) primary breast cancer (BC). LOH,
loss of heterozygosity; HED, hemizygous deletion; HD, homozygous deletion; MA-1, microsatellite size alteration of one allele; LOH + MA, loss of
one allele and size alteration of the other; RH, retention of heterozygosity (for informative markers); RA, retention of both alleles (for non-
informative markers); NI, non informative; M, presence of methylation; –, absence of methylation; WD, well differentiated; MD, moderately
differentiated; PD, poorly differentiated tumor grades; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; pre, pre-menopausal; post,
post-menopausal; na, not applicable.
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indicating the importance of chr.3p22.3 in the development of
BC. Overall alterations (deletion/methylation) of hMLH1 and
RBSP3/HYA22 in group-A were 51% and 49%, respectively,
which was comparatively higher than that seen in group-B (39%
each) (Fig. 5). Significant association was seen between overall
alterations of hMLH1 and RBSP3/HYA22 in group-A (P = 0.002).
Deletion and methylation in hMLH1 and RBSP3/HYA22 were
significantly associated in both group-A (P = 0.01 and 0.0007)
and group-B (P = 0.01 and 0.02) (Table 3).
Expression analysis. Q-PCR analysis of hMLH1 and RBSP3/
HYA22 mRNA revealed reduced expression in both the genes.
With respect to non-tumor control, fold reduction in expression
in tumors was seen in the following order: hMLH1 (10.4 ± 13.9)
and RBSP3/HYA22 (28.9 ± 39.1). Reduced expression was noted
in about 33–40% of the tumors, more than the mean fold
reduction of the respective genes (Fig. 6). Immunohistochemical
analysis revealed intense nuclear localization of hMLH1 protein
in samples without any alteration (deletion and/or methylation),
whereas moderate to negative expression was observed in samples
harboring genetic and/or epigenetic alterations. Expression of
hMLH1 protein showed significant concordance with its alteration
(deletion/methylation) status (P = 0.0004) (Table 4, Fig. 7). The
protein expression of RBSP3/HYA22 was not checked owing to
the lack of commercially available antibody.
Association with other candidate genes. Among the 106 BC
samples, a subset of 29 group-A and 33 group-B samples were
Fig. 2. Schematic representation of the pattern of alterations in chromosome 3p22.3 in late-onset (>40 years) primary breast cancer.
Table 2. Association between 4 candidate tumor suppressor genes loci at chr.3p22.3 in early and late-onset breast cancer
Group-A Group-B
hMLH1 APRGI ITGA9 RBSP3 hMLH1 APRGI ITGA9 RBSP3
D+ D– D+ D– D+ D– D+ D– D+ D– D+ D– D+ D– D+ D–
hMLH1 D+ – – 4 8 6 6 11 1 – – 2 10 4 8 5 7
D– 1 34 1 34 3 32 2 45 4 43 9 38
P-value na 0.003* 0.0001* 0.0000001* na 0.13 0.02* 0.1
APRG1 D+ – – – – 4 1 5 0 – – – – 4 0 3 1
D– 3 39 9 33 4 51 11 44
P-value na na 0.00001* 0.0002* na na 0.0000002* 0.01*
ITGA9 D+ – – – – – – 7 0 – – – – – – 6 2
D– 7 33 8 43
P-value na na na 0.00001* na na na 0.0002*
Abbreviations used are: D+: Deletion positive; D–: Deletion negative; *indicates P-value significance.
Fig. 3. Representative samples showing: (a) LOH, loss of heterozygosity;
(b). MA-1, microsatellite size alteration of one allele; (c). LOH + MA, loss
of one allele and size alteration of other; and (d) homozygous/
hemizygous deletion (HD/HED). Arrowhead (→) indicates loss of
corresponding allele and star () indicates size alteration of one or
both alleles.
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further studied to find out the association of hMLH1 with other
DNA repair genes BRCA1, BRCA2, TP53 and RBSP3/HYA22
with Rb. Deletion status of these genes was published in our
previous report.(9) A majority (64–90%) of the samples in either
group showed alterations in any one of the DNA repair genes
(data not shown). Coincidental alterations of other genes along
with hMLH1 alterations were as follows: group-A: BRCA1
(52%: 15/29); BRCA2 (45%: 13/29); TP53 (28%: 9/29) and
group-B: BRCA1 (27%: 9/33); BRCA2 (21%: 7/33); TP53 (27%:
9/33), indicating involvement of multiple DNA repair pathways.
Similar to DNA repair genes, 67–79% samples showed alterations
of RBSP3/HYA22 and/or Rb in both age groups, suggesting the
importance of this pathway in the development of BC. However,
the coincidental alteration of RBSP3/HYA22 and Rb was less
frequent (21–27%) in both groups.
Clinico-pathological association and patient survival. In group-A,
overall alterations of both hMLH1 and RBSP3/HYA22 were
significantly associated with higher histological grades (P = 0.03
and 0.004). Moreover, hMLH1 deletion showed significant
association with lymph node invasion in group-A (P = 0.01) and
with more advanced stages in group-B (P = 0.03). On the other
hand, methylation of RBSP3/HYA22 showed significant association
with higher tumor grades in group-A (P = 0.002) and lymph
node metastasis in group-B (P = 0.04).
In both age groups of BC, presence of alterations (deletion
and/or methylation) in hMLH1 showed significantly poor patient
survival as revealed by Kaplan–Meier analysis. Contrastingly,
only group-A patients with alterations in RBSP3/HYA22 had
poor disease outcome (Fig. 8).
Discussion
Differential pattern of alterations of different chromosomal
regions in early and late-onset BC has been reported in our
previous studies.(6,7,9,10) Further study of molecular alterations
(deletion/methylation) of the candidate genes at chr.3p22.3
Fig. 4. (a) Histogram showing pattern of methylation in hMLH1
and RBSP3/HYA22 in two age groups of breast cancer (BC). (b)
Representative agarose gels showing methylation in hMLH1 and RBSP3/
HYA22 done by MSRA. H, HpaII digested DNA; M, MspI digested DNA;
U, undigested DNA. Controls: A 445-bp fragment of β3A adaptin gene
(K1) and 229-bp fragment of RARβ2 exon-1 (K2).
Table 3. Association between deletion and methylation of hMLH1 and HYA22 in two age groups of breast cancer
Group-A Group-B
hMLH1 hMLH1 RBSP3 RBSP3 hMLH1 hMLH1 RBSP3 RBSP3
D+ D– M+ M– D+ D– M+ M– D+ D– M+ M– D+ D– M+ M–
hMLH1 D+ – – 9 3 11 1 8 4 – – 9 3 5 7 8 4
D– 12 23 3 32 10 25 11 36 9 38 11 36
P-value na 0.01* 0.0000001* 0.02* na 0.0007* 0.1 0.004*
hMLH1 M+ – – – – 11 10 11 10 – – – – 10 10 7 13
M– 3 23 7 19 4 35 12 27
P-value na na 0.002* 0.07 na na 0.0006* 0.74
RBSP3 D+ – – – – – – 9 5 – – – – – – 8 6
D– 9 24 11 34
P-value na na na 0.01* na na na 0.02*
Abbreviations used are: D+: Deletion positive; D–: Deletion negative; M+: Methylation positive; M–: Methylation negative. *indicates p value 
significance.
Fig. 5. Patten of overall alterations in hMLH1 and RBSP3/HYA22 at
chr3p22.3.
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Fig. 6. Quantitative real-time–polymerase chain reaction (RT-PCR)
analysis showing hMLH1 and RBSP3/HYA22 mRNA expression in breast
cancer (BC) samples (n = 15). Bars represented the gene expression
normalized to β2-microglobulin and relative to normal counterpart
using the 2-ΔΔCt method as described in Materials and Methods. Bar 1
represents the BC cell line MCF-7 and bars 2–15 represents breast
tumors. Horizontal line indicates the mean fold of reduction of the
respective genes.
Table 4. Immunohistochemical expression status of hMLH1 with
respect to alteration (deletion and/or methylation)
Sample No.
hMLH1 alteration
Deletion/Methylation
Expression
1186 +/+ –
374 –/+ –
4187 –/– +++
3266 +/+ –
5451 –/– +++
5596 –/– +++
3156 +/+ –
324 +/– ++
4131 +/+ –
5051 +/– –
4124 –/+ –
1818 –/+ ++
113 +/+ –
314 –/– +++
5732 +/– –
1865 –/+ –
4671 –/– +++
3025 –/+ –
6155 +/+ –
5375 +/– –
P-value = 0.0004*
Sample no is patient’s registration number. Fig. 7. Immunohistochemistry of hMLH1 gene. Breast cancer samples
showing high (a) or moderate (b) or low/negative (c) expression of
hMLH1 gene. All magnifications are at 20×.
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would provide an in-depth analysis of their association in
pathogenesis of the two separate age groups of BC. Overall
alterations noted in the entire studied locus were comparable in
both age group-A (64%) and group-B (61%), indicating the
importance of chr.3p22.3 in the development of BC. Among the
four candidate TSG studied, deletion frequency of hMLH1 and
RBSP3/HYA22 were significantly higher than APRG1 and
ITGA9, indicating the importance of the former two genes in the
development of BC. In group-A, both hMLH1 and RBSP3/
HYA22 showed higher frequency of overall alterations than in
group-B (Fig. 5). This is the first report of its kind to show
differential patterns of alteration in hMLH1 and RBSP3/HYA22
genes in the two age groups of BC.
Significant association between deletion and methylation of
hMLH1 and RBSP3/HYA22 in both groups suggested them to be
candidate TSG in BC. Concordant down-regulation of mRNA
and protein as a consequence of alterations (deletion/methylation)
in these genes further confirmed this contention. Sporadic BC
samples having MSI in other chromosomal arms have been
reported to show frequent mutation and methylation of the DNA
mismatch repair gene hMLH1.(19,37) On the contrary, we have
seen infrequent MSI in different chromosomal arms in primary
BC.(6,7,9,10,38) This might be due to differences in etiology, ethnicity
and probably methods used in the analysis. Hypermethylation of
hMLH1 promoter accounted for the majority of the cases with
reduced expression of hMLH1.(19,20) A similar result was also
observed in the present study. The clinico-pathological associa-
tion of hMLH1 with progression and prognosis of BC has not
yet been reported. Significant association of hMLH1 deletions
with lymph node invasion in group-A and with advanced stages
in group-B as well as adverse patient outcome with hMLH1
alterations in both age groups indicate hMLH1 to be a good
diagnostic and prognostic marker. Moreover, high incidence
hMLH1 alterations along with other DNA repair genes like
BRCA1/BRCA2 in group-A suggested altered pathogenesis in
the two age groups of BC.
Alterations of another candidate TSG, RBSP3/HYA22 also
localized in chr.3p22.3, have been implicated in a number of
epithelial malignancies. The primary function of RBSP3/HYA22
is dephosphorylation of phosphorylated retinoblastoma gene
(ppRb) thus preventing E2F-mediated downstream transcrip-
tional signaling, leading to a block of the cell cycle at the G1–S
boundary.(27–29) Frequent homozygous (HD) and hemizygous
deletion (HED) of this locus have been reported in BC.(39) In
acute lymphoid leukemias (ALL) frequent methylation of RBSP3/
HYA22 promoter have been reported that correlated with decreased
gene expression.(40) However, very few reports exist regarding
molecular alterations of RBSP3/HYA22 and its association with
BC. We, for the first time, have showed that RBSP3/HYA22
indeed undergoes frequent and differential pattern of alterations
in both early and late-onset BC. Clinico-pathological studies
showed methylation of RBSP3/HYA22 to be significantly associ-
ated with higher tumor grades in group-A and with lymph node
invasion in group-B. The association noted between RBSP3/
HYA22 alterations and adverse patient survival in group-A sug-
gested its usefulness as a prognostic tool in this age group.
Moreover, frequent alterations of RBSP3/HYA22 and/or Rb
indicated ablation of the RBSP3/HYA22-Rb-E2F associated cell
cycle pathway in BC.
It is evident from the present study that hMLH1 and RBSP3/
HYA22 are frequently altered (deletion/methylation) in primary
BC, but are differentially associated in the two age groups.
Thus, it is suggested that the dysregulation of the DNA repair
pathways and G1–S cell cycle checkpoint might give some
selective growth advantage for progression and adverse prognosis
of the disease.
Fig. 8. Kaplan–Meier 5-year survival probability
curves with cumulative survival of breast cancer
(BC) patients by overall alteration status of (a)
hMLH1 and (b) RBSP3/HYA22 in early-onset BC
and (c) only hMLH1 in late-onset BC. Survival
time was defined as the time from surgery to the
patient’s death, known recurrence or the last
time the patient was known to be alive. The log
rank test was used to assess the differences in
the patient survival between cases with plot for
the differences in overall survival among cases
with any alteration (Alteration +ve) and no
alteration (Alteration –ve) of the analyzed genes.
The dotted line represents survival probability
without alteration and smooth line represents
with alteration probability. N total number of
early-onset BC.
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